Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pinocembrin Alleviates Gingival Fibroblast Senescence in a Mouse Model of Periodontitis Via CYP1B1 Downregulation.

International dental journal·2026
Same author

Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies.

Pharmacology research & perspectives·2026
Same author

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same author

Inhibition of NHE1 induces trophoblast cell senescence via ADGRG6 mediated by CXCL8.

Journal of reproductive immunology·2026
Same author

Association Between Polymorphisms of 4 Common Genes and High Myopia Risk: A Comprehensive Analysis.

Medical science monitor : international medical journal of experimental and clinical research·2026
Same author

Neuroprotective effects of traditional Chinese medicine using zebrafish models - a review.

Frontiers in pharmacology·2026

Related Experiment Video

Updated: Jun 25, 2026

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization
10:06

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Published on: September 2, 2022

Genetically engineered normal flora for oral polypeptide delivery: dose-absorption response.

Gagan Kaushal1, Jun Shao

  • 1School of Pharmacy, University of Charleston, 2300 MacCorkle Ave. S.E., Charleston, West Virginia 25304, USA.

Journal of Pharmaceutical Sciences
|March 7, 2009
PubMed
Summary
This summary is machine-generated.

Genetically modified Lactococcus lactis (L. lactis) enhanced beta-lactamase oral delivery in rats. This probiotic vector significantly improved drug bioavailability and sustained release compared to traditional solutions.

More Related Videos

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice
12:12

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

Published on: February 8, 2016

Related Experiment Videos

Last Updated: Jun 25, 2026

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization
10:06

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Published on: September 2, 2022

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice
12:12

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

Published on: February 8, 2016

Area of Science:

  • Microbiology
  • Pharmacology
  • Biotechnology

Background:

  • Probiotic bacteria like Lactococcus lactis (L. lactis) offer potential for oral drug delivery.
  • Beta-lactamase is an enzyme with therapeutic applications that requires effective oral delivery methods.
  • Current oral delivery methods for enzymes often suffer from low bioavailability.

Purpose of the Study:

  • To evaluate the efficacy of genetically modified L. lactis as a vector for oral beta-lactamase delivery in rats.
  • To compare the oral bioavailability and pharmacokinetic parameters of beta-lactamase delivered via L. lactis versus a free solution.
  • To investigate the potential of L. lactis as a sustained-release system for oral drug delivery.

Main Methods:

  • Genetically modified L. lactis was engineered to secrete beta-lactamase.
  • Rats were administered three different doses of L. lactis (1.2 x 10(7), 3 x 10(7), and 8 x 10(7) CFU).
  • Beta-lactamase absorption and bioavailability were measured and compared to rats receiving free beta-lactamase solution.

Main Results:

  • L. lactis administration resulted in dose-dependent increases in beta-lactamase absorption (145-364 mU) and bioavailability (8.7%-20.8%).
  • Free beta-lactamase solution showed significantly lower bioavailability (4.7%-5.9%).
  • L. lactis significantly increased oral bioavailability (p < 0.01) and demonstrated sustained release characteristics (increased MAT value, p < 0.01) compared to the solution.

Conclusions:

  • Genetically modified L. lactis serves as an effective oral delivery vector for beta-lactamase in rats.
  • L. lactis significantly enhances oral bioavailability and provides sustained release of beta-lactamase.
  • A linear relationship exists between L. lactis dosage and pharmacokinetic parameters within the studied dose range.